Despite such findings, the effects of CXCL13 expression on clinical outcomes remain controversial, particularly in terms of the association between high infiltration of CXCL13+ CD8+ T cells in tumor lesions and poor clinical outcomes (65, 66). This evidence concerns the gene CD8A and neoplasm.